Armenia grants Agenus first marketing approvals for Botvymo-Evamplix combo in MSS metastatic colorectal cancer
AGEN•Armenia granted the first marketing authorizations worldwide for Agenus’ Botvymo (botensilimab) and Evamplix (balstilimab) as a combination regimen. The conditional approvals took effect Oct. 2, 2026, covering previously treated adults with MSS metastatic colorectal cancer without active liver metastases, and are renewable annually with clinical updates.
1. Conditional approvals
Armenia granted the first marketing authorizations worldwide for Agenus’ Botvymo and Evamplix as a combination regimen for previously treated adults with MSS metastatic colorectal cancer without active liver metastases. The authorizations took effect Oct. 2, 2026, are conditional for one year and are renewable with annual clinical updates.
